TransMedics Group, Inc. (TMDX)
NASDAQ: TMDX · Real-Time Price · USD
77.20
-5.72 (-6.90%)
At close: Nov 20, 2024, 4:00 PM
77.00
-0.20 (-0.26%)
Pre-market: Nov 21, 2024, 7:41 AM EST
TransMedics Group Stock Forecast
Stock Price Forecast
The 11 analysts with 12-month price forecasts for TransMedics Group stock have an average target of 123.73, with a low estimate of 95 and a high estimate of 178. The average target predicts an increase of 60.27% from the current stock price of 77.20.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for TMDX stock from 11 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 3 | 3 | 3 | 4 |
| Buy | 5 | 5 | 5 | 6 | 6 | 5 |
| Hold | 1 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 9 | 10 | 11 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $180 → $110 | Buy | Maintains | $180 → $110 | +42.49% | Nov 20, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $109 → $104 | Strong Buy | Maintains | $109 → $104 | +34.72% | Nov 20, 2024 |
| TD Cowen | TD Cowen | Strong Buy Maintains $175 → $120 | Strong Buy | Maintains | $175 → $120 | +55.44% | Nov 18, 2024 |
| Piper Sandler | Piper Sandler | Buy Reiterates $180 | Buy | Reiterates | $180 | +133.16% | Oct 29, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $200 → $125 | Buy | Maintains | $200 → $125 | +61.92% | Oct 29, 2024 |
Financial Forecast
Revenue This Year
442.77M
from 241.62M
Increased by 83.25%
Revenue Next Year
559.10M
from 442.77M
Increased by 26.27%
EPS This Year
1.09
from -0.77
EPS Next Year
1.69
from 1.09
Increased by 54.84%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 464.6M | 607.0M | 750.8M | ||
| Avg | 442.8M | 559.1M | 670.7M | ||
| Low | 416.4M | 498.5M | 594.8M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 92.3% | 37.1% | 34.3% | ||
| Avg | 83.2% | 26.3% | 20.0% | ||
| Low | 72.3% | 12.6% | 6.4% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 1.52 | 2.16 | 4.22 | ||
| Avg | 1.09 | 1.69 | 2.66 | ||
| Low | 0.91 | 1.12 | 1.76 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | 98.6% | 150.2% | ||
| Avg | - | 54.8% | 57.7% | ||
| Low | - | 2.6% | 4.6% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.